Iterum Historical Financial Ratios

ITRM Stock  USD 2.02  0.01  0.49%   
Iterum Therapeutics is lately reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 10.3 K or Invested Capital of 0.0 will help investors to properly organize and evaluate Iterum Therapeutics PLC financial condition quickly.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Iterum Financial Ratios Analysis

Iterum Therapeutics PLCFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Iterum Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Iterum financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Iterum Therapeutics history.

Iterum Therapeutics Financial Ratios Chart

At this time, Iterum Therapeutics' Capex To Revenue is very stable compared to the past year. As of the 1st of December 2024, ROE is likely to grow to 6.29, though Book Value Per Share is likely to grow to (0.47).
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Iterum Therapeutics PLC stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Iterum Therapeutics sales, a figure that is much harder to manipulate than other Iterum Therapeutics PLC multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.
Most ratios from Iterum Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Iterum Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
At this time, Iterum Therapeutics' Capex To Revenue is very stable compared to the past year. As of the 1st of December 2024, ROE is likely to grow to 6.29, though Book Value Per Share is likely to grow to (0.47).
 2023 2024 (projected)
Graham Number5.745.45
Receivables Turnover0.03850.0366

Iterum Therapeutics fundamentals Correlations

-0.391.0-0.82-0.370.55-0.88-0.391.00.550.26-0.690.590.720.45-0.7-0.79-0.240.940.86-0.24-0.69-0.380.54-0.310.17
-0.39-0.390.290.09-0.120.381.0-0.39-0.12-0.69-0.05-0.130.140.430.330.27-0.37-0.11-0.43-0.37-0.28-0.31-0.59-0.34-0.03
1.0-0.39-0.82-0.370.55-0.88-0.391.00.550.26-0.690.590.720.45-0.7-0.79-0.240.940.86-0.24-0.69-0.380.54-0.310.17
-0.820.29-0.820.0-0.930.480.29-0.82-0.93-0.210.58-0.94-0.59-0.350.21.00.27-0.77-0.460.270.550.39-0.50.30.15
-0.370.09-0.370.00.250.610.09-0.370.250.450.710.22-0.620.050.63-0.05-0.43-0.45-0.62-0.430.44-0.05-0.39-0.38-0.93
0.55-0.120.55-0.930.25-0.12-0.120.551.00.13-0.41.00.420.260.17-0.94-0.270.530.09-0.27-0.4-0.380.33-0.27-0.33
-0.880.38-0.880.480.61-0.120.38-0.88-0.12-0.180.64-0.16-0.66-0.390.950.430.14-0.84-1.00.140.620.25-0.480.21-0.39
-0.391.0-0.390.290.09-0.120.38-0.39-0.12-0.69-0.05-0.130.140.430.330.27-0.37-0.11-0.43-0.37-0.28-0.31-0.59-0.34-0.03
1.0-0.391.0-0.82-0.370.55-0.88-0.390.550.26-0.690.590.720.45-0.7-0.79-0.240.940.86-0.24-0.69-0.380.54-0.310.17
0.55-0.120.55-0.930.251.0-0.12-0.120.550.13-0.41.00.420.260.17-0.94-0.270.530.09-0.27-0.4-0.380.33-0.27-0.33
0.26-0.690.26-0.210.450.13-0.18-0.690.260.130.480.13-0.43-0.07-0.2-0.21-0.14-0.020.2-0.140.3-0.05-0.04-0.15-0.54
-0.69-0.05-0.690.580.71-0.40.64-0.05-0.69-0.40.48-0.43-0.97-0.390.460.560.04-0.8-0.610.040.840.33-0.550.09-0.58
0.59-0.130.59-0.940.221.0-0.16-0.130.591.00.13-0.430.450.280.14-0.96-0.270.570.13-0.27-0.43-0.370.36-0.28-0.3
0.720.140.72-0.59-0.620.42-0.660.140.720.42-0.43-0.970.450.58-0.48-0.58-0.240.820.61-0.24-0.94-0.510.41-0.290.46
0.450.430.45-0.350.050.26-0.390.430.450.26-0.07-0.390.280.58-0.33-0.35-0.910.510.32-0.91-0.81-0.84-0.21-0.93-0.26
-0.70.33-0.70.20.630.170.950.33-0.70.17-0.20.460.14-0.48-0.330.140.1-0.65-0.950.10.480.19-0.30.17-0.41
-0.790.27-0.791.0-0.05-0.940.430.27-0.79-0.94-0.210.56-0.96-0.58-0.350.140.28-0.74-0.40.280.540.39-0.480.310.18
-0.24-0.37-0.240.27-0.43-0.270.14-0.37-0.24-0.27-0.140.04-0.27-0.24-0.910.10.28-0.24-0.081.00.510.750.31.00.62
0.94-0.110.94-0.77-0.450.53-0.84-0.110.940.53-0.02-0.80.570.820.51-0.65-0.74-0.240.81-0.24-0.78-0.350.47-0.30.29
0.86-0.430.86-0.46-0.620.09-1.0-0.430.860.090.2-0.610.130.610.32-0.95-0.4-0.080.81-0.08-0.56-0.170.53-0.160.4
-0.24-0.37-0.240.27-0.43-0.270.14-0.37-0.24-0.27-0.140.04-0.27-0.24-0.910.10.281.0-0.24-0.080.510.750.31.00.63
-0.69-0.28-0.690.550.44-0.40.62-0.28-0.69-0.40.30.84-0.43-0.94-0.810.480.540.51-0.78-0.560.510.75-0.130.56-0.24
-0.38-0.31-0.380.39-0.05-0.380.25-0.31-0.38-0.38-0.050.33-0.37-0.51-0.840.190.390.75-0.35-0.170.750.750.350.750.29
0.54-0.590.54-0.5-0.390.33-0.48-0.590.540.33-0.04-0.550.360.41-0.21-0.3-0.480.30.470.530.3-0.130.350.260.34
-0.31-0.34-0.310.3-0.38-0.270.21-0.34-0.31-0.27-0.150.09-0.28-0.29-0.930.170.311.0-0.3-0.161.00.560.750.260.58
0.17-0.030.170.15-0.93-0.33-0.39-0.030.17-0.33-0.54-0.58-0.30.46-0.26-0.410.180.620.290.40.63-0.240.290.340.58
Click cells to compare fundamentals

Iterum Therapeutics Account Relationship Matchups

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.76)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.73)
Return On Equity
(5.56)
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.